Prothena Corporation News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

29.09.16	Prothena Outlines Phase 2 Development Strategy for PRX003 (GlobeNewswire)
26.09.16	Prothena Announces President and CEO Dr. Dale B. Schenk to Take Medical Leave (GlobeNewswire)
22.09.16	Prothena to Host Update on PRX003 Phase 2 Development Strategy (GlobeNewswire)
06.09.16	Prothena Announces Appointment of Gene G. Kinney as Chief Operating Officer (GlobeNewswire)
30.08.16	Prothena to Participate in Upcoming September Investor Conferences (GlobeNewswire)
02.08.16	Prothena Reports Second Quarter 2016 Financial Results; Provides R&D Update (GlobeNewswire)
06.07.16	Prothena to Participate in Cantor Fitzgerald's 2nd Annual Healthcare Conference (GlobeNewswire)
05.07.16	Prothena Presents New Data from Phase 1/2 Study of NEOD001 Demonstrating Improvements in Three Organ Systems in Previously-Treated Patients with AL Amyloidosis (GlobeNewswire)
21.06.16	Prothena to Present at 15th International Symposium on Amyloidosis Showcasing Broad Commitment to... (GlobeNewswire)
10.06.16	MRK Opens Wallet, VRX To Face FDA Panel In July, SPHS Vaults On Trial Data (RTTNews)
09.06.16	Prothena Reports Results of Phase 1 Single Ascending Dose Study of PRX003, Demonstrating Target Engagement of the Novel Anti-MCAM Antibody for Inflammatory Diseases (GlobeNewswire)
23.05.16	Prothena to Present Wide Range of Studies on Amyloidosis, Including New Clinical Data on NEOD001, at International Symposium on Amyloidosis (GlobeNewswire)
19.05.16	Prothena to Present Quality of Life Data on AL Amyloidosis at European Hematology Association 21st Congress (GlobeNewswire)
09.05.16	Prothena to Present Clinical Results From its Phase 1 Single Ascending Dose Study of PRX003, an Anti-MCAM Antibody Being Investigated for Inflammatory Diseases, at EULAR 2016 (GlobeNewswire)
04.05.16	EVOK Expects Data In Q3, PRTA Has Its Hands Full, SUPN Awaits FDA Decision (RTTNews)
03.05.16	Prothena Reports First Quarter 2016 Financial Results and Provides R&D Update (GlobeNewswire)
16.03.16	Data from Prothena's Preclinical Program on Conformation-Specific Antibodies Against Misfolded Transthyretin Published in Amyloid (GlobeNewswire)
29.02.16	Prothena to Present Preclinical Data for PRX003 at 2016 AAAAI Annual Meeting (GlobeNewswire)
24.02.16	Prothena Announces Appointment of Chief Commercial Officer (GlobeNewswire)
18.02.16	Prothena Reports Fourth Quarter and Full Year 2015 Financial Results; Provides Financial Guidance and R&D Update (GlobeNewswire)
09.02.16	Data From Prothena's Ongoing Phase 1/2 Clinical Trial of NEOD001 in AL Amyloidosis Published in the Journal of Clinical Oncology (GlobeNewswire)
04.02.16	Prothena to Report Fourth Quarter and Full Year 2015 Financial Results and Host Webcast Conference Call on February 18 (GlobeNewswire)
01.02.16	Prothena to Participate in BIO CEO & Investor and Leerink Partners Healthcare Conferences (GlobeNewswire)
07.01.16	Prothena Announces Pricing of Public Offering of 2,250,000 Ordinary Shares (GlobeNewswire)
05.01.16	Prothena Announces Proposed Offering of Ordinary Shares (GlobeNewswire)
01.12.15	Prothena to Participate in Oppenheimer and RBC Capital Markets Healthcare Investor Conferences (GlobeNewswire)
05.11.15	Prothena to Present New Preclinical Data for NEOD001 at 57th Annual American Society of Hematology Meeting (GlobeNewswire)
04.11.15	Prothena to Present at the 2015 Credit Suisse Healthcare Conference on November 10 (GlobeNewswire)
03.11.15	ACAD Gets FDA Date, Insight On BIND, Mega Deals Of Monday, PRTA On Track (RTTNews)
02.11.15	Prothena Reports Third Quarter 2015 Financial Results and Provides R&D Update (GlobeNewswire)
15.10.15	Prothena to Initiate PRONTO, a Global Trial of NEOD001 in Patients With AL Amyloidosis With Primary Endpoint of Cardiac Response (GlobeNewswire)
22.09.15	Prothena to Present at Ladenburg Thalmann 2015 Healthcare Conference on September 29 (GlobeNewswire)
04.08.15	Prothena Reports Second Quarter 2015 Financial Results and Provides R&D Update (GlobeNewswire)
29.06.15	Prothena Announces Addition of Seasoned Executive to Board of Directors (GlobeNewswire)
17.06.15	Prothena Presents Data From A Phase 1 Single Ascending Dose Study Of PRX002 (RTTNews)
17.06.15	Prothena Presents Clinical Results Demonstrating Robust, Rapid Reduction in Levels of Free Serum Alpha-Synuclein of Up to 96% After Single Dose of PRX002... (GlobeNewswire)
16.06.15	Prothena to Present at JMP Securities Life Science Conference 2015 on June 23 (GlobeNewswire)
12.06.15	Prothena's NEOD001 Protein Immunotherapy Clinical Data Highlighted in Oral Presentation at the 20th Congress of the European Hematology Association (GlobeNewswire)
12.06.15	Opportunity to Improve Diagnosis and Treatment of Systemic Amyloidosis Highlighted in Patient Experience Survey Presented at the 20th Congress of the European Hematology Association (GlobeNewswire)
10.06.15	FDA Panel Backs REGN's Cholesterol Drug, SAGE Cheered Up, Keep Watch Over TXMD (RTTNews)
09.06.15	Prothena Announces First Human Dosed in Phase 1 Study of PRX003 for the Treatment of Psoriasis and Other Inflammatory Diseases (GlobeNewswire)
08.06.15	Prothena to Present Clinical Results From Its Phase 1 Single Ascending Dose Study of PRX002 at 19th International Congress of Parkinson's Disease and Movement Disorders (GlobeNewswire)
02.06.15	Prothena Presents Compelling New Data From Ongoing Phase 1/2 Study of NEOD001 in Patients With AL Amyloidosis at 2015 ASCO Annual Meeting (GlobeNewswire)
21.05.15	Prothena Announces Presentation of Clinical Data From the Ongoing Phase 1/2 NEOD001 Study and Systemic Amyloidosis Patient Survey Results at 20th Congress of the European Hematology Association (GlobeNewswire)
13.05.15	Prothena to Present Updated Clinical Data From Ongoing Phase 1/2 Study of NEOD001 at 2015 ASCO Annual Meeting (GlobeNewswire)
05.05.15	Prothena Reports First Quarter 2015 Financial Results and Provides R&D Update (GlobeNewswire)
04.05.15	The Michael J. Fox Foundation and Prothena Partner to Accelerate Discovery of Novel Biomarkers for Parkinson's Disease (GlobeNewswire)
28.04.15	Prothena to Present at Upcoming Investor Healthcare Conferences (GlobeNewswire)
23.04.15	Dr. Dale Schenk to Participate on Expert Panel at World Medical Innovation Forum: Neurosciences (GlobeNewswire)
08.04.15	Prothena Announces Pricing of Public Offering of 3,300,000 Ordinary Shares (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

CieFinRichemont	137.35	1.40 %	K V
Sonova Hldg	297.30	1.29 %	K V
Logitech Intl	74.86	1.22 %	K V
Nestle	75.22	1.02 %	K V
Alcon	76.32	0.95 %	K V
UBS Group	28.17	-0.67 %	K V
Swiss Re	131.95	-0.68 %	K V
Geberit	533.80	-0.78 %	K V
Lonza Grp	541.40	-0.81 %	K V
Kuehne+Nagel Int	202.60	-1.65 %	K V

Nachrichten zu Prothena Corporation PLC

Aktien Top/Flop

Meistgelesene Nachrichten